CA3038106A1 - Compounds and methods for treating lupus - Google Patents

Compounds and methods for treating lupus Download PDF

Info

Publication number
CA3038106A1
CA3038106A1 CA3038106A CA3038106A CA3038106A1 CA 3038106 A1 CA3038106 A1 CA 3038106A1 CA 3038106 A CA3038106 A CA 3038106A CA 3038106 A CA3038106 A CA 3038106A CA 3038106 A1 CA3038106 A1 CA 3038106A1
Authority
CA
Canada
Prior art keywords
alkyl
compound
occurrence
cooh
groups
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3038106A
Other languages
English (en)
French (fr)
Inventor
Fiona Lorraine Scott
Kristen R. Taylor Meadows
Robert Peach
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Receptos LLC
Original Assignee
Celgene International II SARL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene International II SARL filed Critical Celgene International II SARL
Publication of CA3038106A1 publication Critical patent/CA3038106A1/en
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245Oxadiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3038106A 2016-09-29 2017-09-28 Compounds and methods for treating lupus Pending CA3038106A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662401762P 2016-09-29 2016-09-29
US62/401,762 2016-09-29
PCT/US2017/054053 WO2018064356A1 (en) 2016-09-29 2017-09-28 Compounds and methods for treating lupus

Publications (1)

Publication Number Publication Date
CA3038106A1 true CA3038106A1 (en) 2018-04-05

Family

ID=60043386

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3038106A Pending CA3038106A1 (en) 2016-09-29 2017-09-28 Compounds and methods for treating lupus

Country Status (6)

Country Link
US (1) US11278526B2 (cg-RX-API-DMAC7.html)
EP (1) EP3518922A1 (cg-RX-API-DMAC7.html)
JP (1) JP7086945B2 (cg-RX-API-DMAC7.html)
KR (1) KR102408814B1 (cg-RX-API-DMAC7.html)
CA (1) CA3038106A1 (cg-RX-API-DMAC7.html)
WO (1) WO2018064356A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2960051T3 (es) * 2017-05-22 2024-02-29 Egyt Gyogyszervegyeszeti Gyar Proceso para la producción de ozanimod
AR116479A1 (es) 2018-09-25 2021-05-12 Quim Sintetica S A Intermediarios para la síntesis de ozanimod y procedimiento para la preparación del mencionado agonista del receptor de esfingosina-1-fosfato y de dichos intermediarios
EP3947363A4 (en) * 2019-03-29 2023-01-04 Receptos Llc SPHINGOSINE-1-PHOSPHATE RECEPTOR MODULATORS
CN116332794B (zh) * 2021-12-24 2024-10-15 上海合全药物研发有限公司 一种芳基腈类化合物的制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080014009A (ko) 2005-06-08 2008-02-13 노파르티스 아게 폴리시클릭 옥사디아졸 또는 이속사졸, 및 이들의 s1p수용체 리간드로서의 용도
AU2007302262A1 (en) 2006-09-29 2008-04-03 Novartis Ag Oxadiazole derivatives with anti-inflammatory and immunosuppressive properties
JO2701B1 (en) 2006-12-21 2013-03-03 جلاكسو جروب ليميتد Vehicles
PT2291080E (pt) 2008-05-14 2015-10-30 Scripps Research Inst Novos modelamodeladores dos recetores da esfingosina fosfato
CA2780772C (en) * 2009-11-13 2018-01-16 Receptos, Inc. Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis
US20170165236A1 (en) * 2013-11-01 2017-06-15 Celgene International Ii Sàrl Selective sphingosine 1 phosphate receptor modulators and combination therapy therewith

Also Published As

Publication number Publication date
KR20190060791A (ko) 2019-06-03
WO2018064356A1 (en) 2018-04-05
JP7086945B2 (ja) 2022-06-20
EP3518922A1 (en) 2019-08-07
US20190224172A1 (en) 2019-07-25
KR102408814B1 (ko) 2022-06-14
JP2019529487A (ja) 2019-10-17
US11278526B2 (en) 2022-03-22

Similar Documents

Publication Publication Date Title
JP2021178852A (ja) Hivプロテアーゼ阻害剤としての1−ベンジル−2−イミノ−4−フェニル−5−オキソイミダゾリジン誘導体
JP5988379B2 (ja) スフィンゴシン−1−リン酸受容体変調因子および不斉合成方法
CN110088105B (zh) Jak家族激酶的小分子抑制剂
EA021672B1 (ru) Модуляторы рецепторов сфингозин-1-фосфата и их применение
US11207301B2 (en) Sphingosine 1 phosphate receptor agonists for neuroprotection
JP6987859B2 (ja) Magl阻害剤
TWI813570B (zh) 作為C5a抑制劑之5-5稠合環
JP2024514990A (ja) ヘテロアルキルジヒドロキノリンスルホンアミド化合物
US20140187554A1 (en) Modulators of the nuclear hormone receptor ror
US11278526B2 (en) Compounds and methods for treating lupus
RU2760303C2 (ru) Соединения бензолсульфонамидов и их использование в качестве терапевтических средств
TW201742862A (zh) 2-取代之吲唑於治療及預防自體免疫病症之用途
IL233986A (en) History of diaminopyrimidine, their preparation and their pharmaceutical preparations
EP3600301B1 (en) Kdm4 inhibitors
JP7224293B2 (ja) Rorガンマモジュレーター及びその使用
WO2020077361A1 (en) Compounds and methods of their use
JP7138647B2 (ja) Rorガンマモジュレーター及びその使用
TWI537251B (zh) Fpr1拮抗劑的衍生物及其用途
ES2390053T3 (es) Derivado de ácido fenilacético, procedimiento para producir el mismo y uso
JP7254703B2 (ja) Rorガンマモジュレーター及びその使用
Fang et al. Discovery of the First-in-Class RORγ Covalent Inhibitors for Treatment of Castration-Resistant Prostate Cancer
TW201534322A (zh) Fpr1拮抗劑的衍生物及其用途(一)

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220830

EEER Examination request

Effective date: 20220830

EEER Examination request

Effective date: 20220830

EEER Examination request

Effective date: 20220830

EEER Examination request

Effective date: 20220830